Stem cells as an emerging paradigm in stroke 3: enhancing the development of clinical trials

Sean I Savitz, Steven C Cramer, Lawrence Wechsler, STEPS 3 Consortium, Jaroslaw Aronowski, Johannes Boltze, Cesar Borlongan, Casey Case, Thomas Chase, Michael Chopp, S Thomas Carmichael, Steven C Cramer, Pam Duncan, Seth Finklestein, Steven Fischkoff, Raphael Guzman, David C Hess, David Huang, Jim Hinson, Steven Kautz, Douglas Kondziolka, Robert Mays, Vivek Misra, Panos Mitsias, Michael Modo, Keith Muir, Sean I Savitz, John Sinden, Evan Snyder, Gary Steinberg, Farhaan Vahidy, Lawrence Wechsler, Alison Willing, Steven Wolf, Ernest Yankee, Dileep R Yavagal, Sean I Savitz, Steven C Cramer, Lawrence Wechsler, STEPS 3 Consortium, Jaroslaw Aronowski, Johannes Boltze, Cesar Borlongan, Casey Case, Thomas Chase, Michael Chopp, S Thomas Carmichael, Steven C Cramer, Pam Duncan, Seth Finklestein, Steven Fischkoff, Raphael Guzman, David C Hess, David Huang, Jim Hinson, Steven Kautz, Douglas Kondziolka, Robert Mays, Vivek Misra, Panos Mitsias, Michael Modo, Keith Muir, Sean I Savitz, John Sinden, Evan Snyder, Gary Steinberg, Farhaan Vahidy, Lawrence Wechsler, Alison Willing, Steven Wolf, Ernest Yankee, Dileep R Yavagal

No abstract available

Keywords: guideline; stem cells; stroke.

Conflict of interest statement

Disclosures: The University of Texas Health Science Center conducts sponsored research with Athersys, Aldagen, Celgene, and Johnson & Johnson. Dr Savitz serves on the Data Safety Monitoring Board for SanBio and as an employee of the University of Texas Health Science Center is a consultant to KM, NeuralStem, and Mesoblast. The other authors report no conflicts.